Predictive value of microRNA-210 in preeclampsia: a prospective cohort study

Aim To assess the usefulness of circulating miR-210 as a non-invasive molecular biomarker for early prediction of preeclampsia (PE) in high-risk pregnant women. Methods A total of 40 pregnant women between 14 and 26 weeks of gestation associated with any risk factors for PE were enrolled in the study. MicroRNA-210 was detected using real-time polymerase chain reaction (Q-PCR) in the plasma sample. Follow-up of the pregnant women in antenatal clinic was done. The prediction of PE among the study group was evaluated, and also the level of microRNA-210 at which PE occurred was detected. Results Of 40 cases of high-risk pregnant women, 8 cases developed PE, where 2 had pregestational diabetes mellitus (DM), 1 was primigravida with pregestational DM, 1 had chronic hypertension with pregestational DM, and 4 were primigravida alone. The plasma miR-210 was significantly higher in high-risk pregnant women with PE (n = 8), with a mean ± SE of 19.23 ± 6.95 and median of 15.48 compared with those who did not develop PE (n = 32), with mean ± SE of 4.29 ± 1.36 and median of 1.51 (P = 0.001). At a cutoff value of 2.28-fold change, plasma miR-210 was 87.5% sensitive and 68.8% specific for prediction of PE in risk factor pregnant women, with area under the curve of 0.852. Conclusion Plasma miR-210 levels were significantly elevated in preeclamptic women compared with those without PE in high-risk pregnant women, so miR-210 may have possible pathophysiological role in PE.